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Poster Session I S215Beauty (SB) DNA non-viral transposon/transposase system to ex-
press the melanoma-associated antigens MART-1 and gp100 in
combination with desired HLA molecules.
Table 1. Classical HLA class I molecules used to genetically
modify K562 to function as aAPC and their proportion in the
US population and in melanoma patients at MDACC.
Percent ofHLA
class IAfrican-
American
(% of US
population)Caucasian
(% of US
population)Hispanic
(% of US
population)Asian
(% of US
population)stage IV
melanoma
patients
at MDACCA*0101 11 28 12 3 15
A*0201 23 47 41 18 27
A*0301 19 24 14 2 12
A*1101 5 14 11 41 8
A*2301 21 3 4 1 3
A*2402 6 13 23 34 8
A*3303 8 1 2 22 1
B*0702 16 21 12 5
B*3501 12 13 14 7
B*4403 7 6 11 9
B*5101 2 11 12 13We show that these aAPC selectively propagate melanoma-specific
CD81 T cells from both PBMC and TIL, generating T cells with
an improved memory phenotype, expansion capability, and cytolytic
function compared to TIL generated in standard expansion proto-
cols. By ex vivo manipulation of the microenvironment, we can
thus expand T cells with a younger, less differentiated phenotype
which maintain expression of critical T-cell costimulatory molecules
predicted to improve persistence and antitumor function following
ACT. These data suggest that K562-aAPC can be used as a platform
technology for the robust and rapid manufacturing of clinical-grade
melanoma-specific T cells. Furthermore, this aAPC strategy
broadens the application of T cell therapy so that patients from
whom TIL cannot be expanded may receive immunotherapy.167
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Patients receiving allogeneic SCT for hematological malignancies
who suffer a relapse of their disease post-transplant have limited
treatment options and a poor prognosis. With the exception of pa-
tients with chronic leukemias, standard treatment options achieve
less than a 10% median survival beyond 6 months. The primary ob-
jective of this phase II clinical trial is to evaluate the safety and effi-
cacy of using DLI from a haplo-identical donor to treat relapsed
disease following matched sibling stem cell transplantation (SCT)
in subjects who are not candidates for other treatments. SinceMarch
2008 three patients have been enrolled and received preconditioning
with fludarabine 25mg/m2  5 days and cytoxan 60mg/kg  2 days,
followed by a haploidentical DLI from a family member at a fixed
dose of 1  10*8th CD31 T cells/kg. Median age was 55 years
(range, 40-57). Two patients were enrolled to treat relapsed AML
occurring day 70 and 83, and one patient for ALL relapse occurring
day 91 after SCT. All patients had active disease at time of precondi-
tioning, resistant to standard chemotherapy. Two patients had nor-
mal cytogenetics, and one was positive for FLT3-ITD. All patients
experience a cytokine storm occurring within 12 hours of DLI and
manifesting as a diffuse macular rash, mild transaminitis, and persis-
tent fever (. 40 C) resolving with high dose steroids (1-2 mg/Kg
methylprednisolone). All patients experienced a hematologic remis-
sion of their disease (2 with no evidence of disease on bone marrow
biopsy), and developed marrow aplasia. All patients developed gradeII skin GvHD. Two patients experienced grade III-IV acute GvHD
of liver and GI tract that contributed to death in one patient 18 days
after DLI. Two patients received a haploidentical CD34 selected
stem cell rescue from the same haploidentical donor on days 35
and 38 after DLI to treat persisting cytopenia. Engraftment of all
lineages occurred within 14 days of stem cell infusion. Upon engraft-
ment, one patient was discharged home but died day 103 of recurrent
AML, and one had persistence of pulmonary and hepatic fungal in-
fection that resulted in death on day 64 after DLI. Overall, treatment
of relapsed leukemia in these 3 patients with mismatched DLIs
preconditioned with fludarabine and cytoxan produced a potent
anti-leukemic effect, but was associated with a high incidence of
treatment-related mortality due to acute GvHD andmarrow aplasia.
Table 1.
SurvivalPatientMarrow
AplasiaBacterial
InfectionsFungal
InfectionsSevere
GvHDafter
relapse
(days)Survival
after
DLI (days)Cause
of death1 YES YES NO YES 35 18 TRM2 YES YES Pulmonary NO 190 103 Relapse3 YES YES Pulmonary YES 77 64 TRM168
THE GENERATION OF CLINICAL GRADE ASPERGILLUS FUMIGATUS (AF)
SPECIFIC IMMUNE CELLS FOR ADOPTIVE IMMUNOTHERAPY
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waiteGottlieb, D. Westmead Millennium Institute and University of Syd-
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Af is responsible for themajority of invasive fungal infections post-
allogeneic HSCT due principally to transplant related neutropenia
and impaired specific immunity. Murine models suggest that the lat-
ter may be amenable to correction with adoptive immunotherapy
providing lymphocytes specific for Af. However, an efficient, repro-
ducible and clinically acceptable method for the expansion of such
cells in humans is not currently available. Specific T cell responses
to fungi are thought to be mediated by CD4 cells of the Th1 and
Th17 type. Recently, we developed a procedure that induces expan-
sion of large numbers of Af specific T cells over a 21 day culture pe-
riod. This procedure incorporates 2 stimulations using autologous
monocyte-derived dendritic cells pulsed with water-soluble antigen,
and subsequent expansion of T cells using IL-2, IL-7 and IL-15. Our
method satisfies clinical regulatory standards. Using water soluble
antigen from an Af isolate (WMAfES001), we expanded T cells
from PBMCs from 5 healthy donors. Median expansion was 38.3
fold following stimulation with WMAfES001 antigen pulsed DCs
compared with 9.0 when stimulated with unpulsed DCs. The
mean percentages of CD3, CD4 and CD8 T cells in WMAfES001
cultures were 96.364.6%, 94.463.3% and 4.363.0% respectively.
The specificity of T cells in 4 cultures was assessed by cytokine pro-
duction upon re-stimulation with DCs pulsed with WMAfES001
and expressed as a fold increase relative to cytokine levels in response
tomock antigen.Median fold increases of 9.6 in IFNg, 8.3 in TNFa,
11.0 in IL-2 and 3.7 in IL-17 were observed in the CD4T cell subset
of WMAfES001 expanded cultures. Amongst the Th1 cytokine
producers, 51.163.2% produced a single cytokine, 40.769.7% pro-
duced double cytokines and 8.366.9% produced all three cytokines.
Stimulation of Af expanded cells with antigen from a clinical Af iso-
late resulted in cytokine production similar to that we observed in
our clinical grade WMAfES001 expanded cultures. No cytokine
response was observed in CD8 lymphocytes fromWMAfES001 cul-
tures, unmanipulated PBMCs, or cultures expanded in the absence of
WMAfES001 antigens. In conclusion, we have generated a clinically
appropriate Af antigen preparation and a reliable procedure for the
expansion of Af specific T cells for cell therapy purposes that results
in high absolute numbers of specific Th1 andTh17 cytokine produc-
ing cells. These cells are ready to be tested clinically in situations of
high Af risk.
